See more : MSP Recovery, Inc. (LIFWW) Income Statement Analysis – Financial Results
Complete financial analysis of NextCure, Inc. (NXTC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NextCure, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Anker Innovations Limited (300866.SZ) Income Statement Analysis – Financial Results
- Bagger Dave’s Burger Tavern, Inc. (BDVB) Income Statement Analysis – Financial Results
- Stolt-Nielsen Limited (SNI.OL) Income Statement Analysis – Financial Results
- ADF Group Inc. (DRX.TO) Income Statement Analysis – Financial Results
- City Development Environment CO.,Ltd. (000885.SZ) Income Statement Analysis – Financial Results
NextCure, Inc. (NXTC)
About NextCure, Inc.
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4; and NC525, a novel LAIR-1 antibody which is in Preclinical trails that targets acute myeloid leukemia, blast cells, and leukemic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 22.38M | 6.35M | 0.00 | 0.00 |
| Cost of Revenue | 3.68M | 4.48M | 4.30M | 46.55K | 34.22K | 1.68M | 582.00K |
| Gross Profit | -3.68M | -4.48M | -4.30M | 22.33M | 6.31M | -1.68M | -582.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 99.79% | 99.46% | 0.00% | 0.00% |
| Research & Development | 47.93M | 54.20M | 50.19M | 46.55M | 34.22M | 19.79M | 12.95M |
| General & Administrative | 19.71M | 21.71M | 20.57M | 17.05M | 9.61M | 3.41M | 2.60M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 19.71M | 21.71M | 20.57M | 17.05M | 9.61M | 3.41M | 2.60M |
| Other Expenses | 0.00 | 1.18M | 1.38M | 4.62M | 3.75M | 397.00K | 80.00K |
| Operating Expenses | 67.64M | 75.91M | 70.77M | 63.60M | 43.83M | 23.20M | 15.55M |
| Cost & Expenses | 67.64M | 75.91M | 70.77M | 63.60M | 43.83M | 23.20M | 15.55M |
| Interest Income | 0.00 | 1.17M | 1.32K | 4.55K | 3.75K | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 77.00K | 183.00K | 209.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 3.68M | 4.48M | 4.30M | 3.41M | 2.69M | 1.68M | 582.00K |
| EBITDA | -59.04M | -70.25M | -65.01M | -37.81M | -34.79M | -21.10M | -14.97M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | -184.22% | -548.20% | 0.00% | 0.00% |
| Operating Income | -67.64M | -75.91M | -70.77M | -41.23M | -37.48M | -23.20M | -15.55M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | -184.22% | -590.55% | 0.00% | 0.00% |
| Total Other Income/Expenses | 4.91M | 1.18M | 1.38M | 4.62M | 3.75M | 397.00K | 80.00K |
| Income Before Tax | -62.72M | -74.73M | -69.39M | -36.60M | -33.74M | -22.80M | -15.47M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | -163.57% | -531.54% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -5.30M | 6.96M | -3.41M | 2.52M | 397.00K | 0.00 |
| Net Income | -62.72M | -69.43M | -69.39M | -33.19M | -33.74M | -22.80M | -15.47M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | -148.32% | -531.54% | 0.00% | 0.00% |
| EPS | -2.25 | -2.50 | -2.51 | -1.21 | -2.15 | -2.27 | -1.54 |
| EPS Diluted | -2.25 | -2.50 | -2.51 | -1.21 | -2.15 | -2.27 | -1.54 |
| Weighted Avg Shares Out | 27.84M | 27.74M | 27.62M | 27.53M | 15.70M | 10.04M | 10.04M |
| Weighted Avg Shares Out (Dil) | 27.84M | 27.74M | 27.62M | 27.53M | 15.70M | 10.04M | 10.04M |
NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024
NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board
NextCure to Present at 23rd Annual Needham Virtual Healthcare Conference
Wall Street's Favorite Penny Stocks? 7 Names That Could Make You Filthy Rich
NextCure Provides Business Update and Reports Full Year 2023 Financial Results
NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advances
NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders
Here's Why NextCure, Inc. (NXTC) Looks Ripe for Bottom Fishing
NextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury
NextCure (NXTC) Down on Shelving Plans to Develop Candidate
Source: https://incomestatements.info
Category: Stock Reports